Continuing Education Credit Form

Recombinant Immunotoxin Therapy of Cancer: A Developing Alternative to Chemotherapy for Cancer and Autoimmune Diseases such as HIV
 

The American Association of Colleges of Nursing will award 1.5 contact hours of continuing education (up to a total of 15 hours for the entire Bench to Bedside series) for viewing this tape/CD-ROM as an educational activity.  This Continuing Education Credit (CEC) Form must be submitted to verify you viewed the tape/CD-ROM and earned the credit. 

Steps

1.      Print this copy of the Continuing Education Credit Form

2.      View the videotape or CD-ROM

3.      Complete all information requested

4.      Copy the completed form for your records of contact hours earned.  No additional verification will be sent to you.

5.      Send original copy of completed form to:  CenterNet/HMTV,  529 14th Street, N.W., Suite 1292, Washington, DC 20045

Recombinant Immunotoxin Therapy of Cancer is part of the Bench to Bedside Video/CD-ROM Series for clinicians.  At the conclusion of this activity, the learner will be able to:
• Identify two monoclonal antibodies now being used to treat cancer
• Describe why it is often necessary to attach a toxic substance to an antibody
• Understand the composition and basic structure of a recombinant immunotoxin.
• Be aware of which diseases have malignant cells which display surface CD22 or CD25 and which of these have responded best to recombinant immunotoxins
• Describe immunotoxin structure and composition
• Describe the pathway of immunotoxin killing of cancer cell.e


(Please print)

 

Name________________________________________________ RN License # and state______________________
                        (Last)                         (M.I.)                        (First)

Address______________________________________________ City/State/Zip_____________________________

 

Date tape viewed______________ CE form printed on:    Signature  _____________________________

 

 

1.   Relationship to program purpose. Learning objectives for “Recombinant Immunotoxin Therapy of Cancer” support the overall purpose for which the series is designed.
___Yes   ___Partially   ___No
       

2.  Objectives   Has this program enabled you to have a better understanding of the objectives  listed above:
___Yes   ___Partially   ___No       

   

3.   Presenters

Please rate effectiveness of each presenter:

Ira Pastan, M.D. _____Somewhat Effective _____Effective _____Very Effective 
Robert J. Kreitman, M.D. _____Somewhat Effective _____Effective _____Very Effective 
David Fitzgerald, Ph.D. _____Somewhat Effective _____Effective _____Very Effective 


4.   Overall Program

Overall this educational activity was:   _____Marginal                       _____Good               _____Excellent

      Comments: